Abstract: Gastric adenocarcinoma is one of the most common malignant tumors and is ranked third in cancer death toll following lung cancer and liver cancer in China. At least two thirds of the new cases with gastric cancer every year are at the advanced stage (AGC, advanced gastric cancer), and the postoperative 5-year survival rate is only 10% to 49%. The peritoneal relapse in the abdominal cavity is the major cause of unfavorable survival rate in these patients, even after radical operation. Over the past 20 years, hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved considerable success in treating gastric carcinoma with peritoneal carcinomatosis. Preventive application of HIPEC for gastric cancer can decrease the peritoneal recurrence, increase the current 5-year survival length, and improve the patients' quality of life. This review summarized the current status of preventive HIPEC for the treatment of locally advanced gastric cancer in China.